Recombinant cell lines expressing membrane proteins and vesicles prepared therefrom

CN118946347APending Publication Date: 2024-11-12EXOCURE SWEDEN AB
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380016253.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-01-20
Filing Date
2023-01-17
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The prior art has failed to identify which molecules are necessary for the anti-inflammatory activity of vesicles and have failed to effectively reduce the inflammatory response.

Method used

Mammalian cells are genetically modified to overexpress specific membrane proteins such as bifunctional heparan sulfate N-deacetylase/N-sulfotransferase 1, ferrous death inhibitor 1, containing cysteine-rich and transmembrane structures vesicles are prepared to reduce inflammatory responses.

Benefits of technology

It effectively reduces the secretion of inflammatory cytokines such as TNF-α and IL-6, demonstrates the anti-inflammatory activity of vesicles, and determines the key membrane proteins involved in anti-inflammatory effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118946347A_ABST
    Figure CN118946347A_ABST
Patent Text Reader

Abstract

The present disclosure provides vesicles prepared from mammalian cell lines that are genetically modified to overexpress one or more membrane proteins provided in the disclosure. Genetically modified cells are also provided. The vesicles may be used in methods of reducing an inflammatory response in a subject in need thereof.
Need to check novelty before this filing date? Find Prior Art

Description

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to U.S. Provisional Application No. 63 / 301,233, filed on January 20, 2022, which is hereby incorporated by reference in its entirety. introduce

[0002] Vesicles have been described, including extracellular vesicles (EV) or microvesicles (MV), nanovesicles (NV) and synthetic eukaryotic vesicles (SyEV). These vesicles have been used as anti-inflammatory agents when produced by mesenchymal stem cells or other stem cells. However, it is not clear which molecules present in these vesicles are necessary for their anti-inflammatory activity. Such molecules can be used to produce vesicles from cells that have been genetically modified to overexpress the molecule.

[0003] The present disclosure provides cells and vesicles from the cells that have been genetically modified to overexpress membrane proteins associated with the anti-inflammatory activity of EV, NV, and SyEV. Summary of the invention

[0004] The present disclosure provides vesicles prepared from a mammalian cell line that is genetically modified to overexpress a membrane protein selected from the group consisting of bifunctional heparan sulfate N-deacetylase / N-sulfotransferase 1 (NDST1), ferroptosis suppressor protein 1 (AIFM2), cysteine-rich and transmembrane domain-containing protein 1 (CYSTM1), cadherin-6 (CDH6), solute carrier family 22 member 18 (SLC22A18), promethin (TMEM159), receptor-type tyrosine-protein phosphatase kappa (PTPRK), and mitochondrial phosphatase inhibitor 1 (MTP1). kappa), prolylendopeptidase FAP (FAP), phospholipid-transporting ATPase ID (ATP8B2), ADP-ribosyl cyclase / cyclic ADP-ribose hydrolase 2 (BST1), reticulon-2 (RTN2), ras-related protein Rap-1A (RAP1A), basigin (BSG), aldehyde dehydrogenase family 3 member B1 (ALDH3B1), calsyntenin-1 (CLSTN1), small VCP / p97-interacting protein (SVIP), GTP-binding protein Rheb (RHEB) Rheb), lysophosphatidic acid receptor 1 (LPAR1), pro-low-density lipoprotein receptor-related protein 1 (LRP1,prolow-density lipoproteinreceptor-related protein 1), receptor-type tyrosine-protein phosphatase F (PTPRF), raftlin (RFTN1), guanine nucleotide-binding protein G(q)subunit alpha (GNAQ), guanine nucleotide-binding protein subunit alpha-11 (GNA11), integrin alpha-8 (ITGA8), roundabout homolog 1 (ROBO1), ADP-ribosylation factor 6 (ARF6), ephrin type-B receptor 2 (EPHB2), transforming protein RhoA (RHOA The main proteins involved in the study include RhoA, proto-oncogene tyrosine-protein kinase Src, synaptobrevin homolog YKT6, Ras-related protein Rab-23, vascular cell adhesion protein 1 (VCAM1), lymphocyte function-associated antigen 3 (CD58), guanine nucleotide-binding protein G(I) / G(S) / G(O) subunit gamma-12 (GNG12), 2',3'-cyclic-nucleotide 3'-phosphodiesterase (CNP), and 1,2',3'-cyclic-nucleotide phosphodiesterase (1,2',3'-cyclic-nucleotide phosphodiesterase (1,2',3'-cyclic-nucleotide phosphodiesterase (1,2',3'-cyclic-nucleotide phosphodiesterase (1,2',3'-cyclic-nucleotide phosphodiesterase (1,2',3'-cyclic-nucleotide phosphodiesterase (1,2',3'-cyclic-nucleotide phosphodiesterase (1,2',3'-cyclic-nucleotide phosphodiesterase (1,2',3'-cyclic-nucleotide phosphodiesterase (1,2',3'-cyclic-nucleotide phosphodiesterase (1,2',3'-cyclic-nucleotide phosphodiesterase (1,2',3'-cyclic-nucleotide 3'-phosphodiesterase), receptor-type tyrosine protein phosphatase eta (PTPRJ,The invention also provides a plurality of proteins and methods for preparing the invention, wherein the proteins include phosphatase eta, guanine nucleotide-binding protein G(s) subunit alpha isoforms short, ARF5, mitochondrial calcium uniporter regulator 1, NUMA1, protein / nucleic acid deglycase DJ-1, V-type immunoglobulin domain-containing suppressor of T-cell activation, CD276, MCAM and phosphatidylserine synthase 2. Genetically modified cells are also provided. The vesicles can be used in a method of reducing an inflammatory response in a subject in need thereof. BRIEF DESCRIPTION OF THE DRAWINGS

[0005] Figure 1 Schematic diagram showing the method of isolating extracellular vesicles (EVs), nanovesicles (NVs), and synthetic eukaryotic vesicles (SyEVs) from mesenchymal stem cells (MSCs).

[0006] Figure 2 is a graph showing the reduction of OMV-induced proinflammatory cytokines by EV, NV or SyEV. OMV (100 ng / mL) was added to RAW 264.7 cells for 3 hours, followed by washing with PBS and treatment with EV, NV or SyEV (10 7 , 10 8 , 10 9 ). Supernatant concentrations of TNF-α (A) and IL-6 (B) were measured by ELISA. **, P<0.01; ***, P<0.001; two-way ANOVA with Tukey's multiple comparison test. Error bars represent SEM. N=3.

[0007] Figure 3A Venn diagram of 605 proteins associated with the gene ontology term "integral component of the membrane" is shown. In each comparison, proteins with a fold change of more than 1.5 were considered upregulated. Proteins with a fold change of less than 1.5 between the two vesicles being compared were considered unchanged.

[0008] Figure 4 Shown in Figure 3 Venn diagram of proteins considered unchanged between vesicle types.

[0009] Figure 5A and 5B Shown in Figure 4 List of proteins considered unchanged in all three comparisons. definition

[0010] The term "vesicle" as used herein refers to a spherical structure containing an internal volume that is separated from the external environment by a lipid bilayer membrane. Vesicles can be secreted by cells or artificially synthesized from cells. Vesicles are usually smaller than the cells from which they are derived.

[0011] The term "outer membrane vesicle" or "OMV" as used herein refers to a vesicle comprising an outer membrane encapsulating periplasmic contents, cytoplasmic contents, and inner membrane components. OMVs include blebs produced by budding of the outer membrane of an organism (e.g., Gram-negative bacteria). Such OMVs may also be referred to as native OMVs. OMVs may also be produced by disrupting Gram-negative bacteria in a hydrophilic solution (e.g., by extrusion, sonication, detergent, or osmotic shock) to force the cells to form vesicles.

[0012] The term "reformation of vesicles (revesiculation)" and its grammatical equivalents used herein refers to the process of opening a vesicle (e.g., a cell-derived vesicle) so that the internal contents of the vesicle are released, followed by separation of the opened lipid bilayer membrane, and closing the opened lipid bilayer membrane to reform the vesicle. Such vesicles are called ghost vesicles (gNV) or synthetic eukaryotic vesicles (SyEV).

[0013] As used herein, the term "non-reformed vesicles" and grammatical equivalents thereof refer to vesicles, such as cell-derived vesicles, that are not ghost vesicles, that have not been subjected to the process of opening the vesicles such that the internal contents of the vesicles are released, followed by separation of the opened lipid bilayer membranes, and closing of the opened lipid bilayer membranes to reform the vesicles. Thus, non-reformed vesicles encapsulate significantly more of the internal contents of the cells from which they are derived, compared to ghost vesicles prepared from the same type of cells.

[0014] As used herein, the term "extracellular vesicle" means a vesicle released by a eukaryotic cell (e.g., a mammalian cell). Some examples of "extracellular vesicles" include exosomes, ectosomes, microvesicles, prostasomes, oncosomes, and apoptotic bodies.

[0015] The term "inflammatory response" as used herein refers to the secretion of proinflammatory cytokines, toll-like receptors (TLRs) and / or activation of systemic inflammation. Some examples of proinflammatory cytokines include IL-6, IL-2, IL-4, IL-6, IL-12, IL-12p70, IL-17, tumor necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ).

[0016] "Isolated" refers to an entity of interest that is in an environment different from that in which it may naturally occur. "Isolated" is meant to include an entity within a sample that is substantially enriched for the entity of interest and / or wherein the entity of interest is partially or substantially purified.

[0017] The terms "subject" and "patient" refer to an animal that is the object of treatment, observation or experiment. By way of example only, a subject includes, but is not limited to, a mammal, including, but not limited to, a human or a non-human mammal, such as a non-human primate, a cow, a horse, a dog, a sheep or a cat.

[0018] The term "treatment" and its variations as used herein encompass any treatment of a disease or condition in a mammal, particularly a human, and include: (a) preventing a subject who may be susceptible to the disease or condition but has not yet been diagnosed with the disease or condition from developing the disease or condition; (b) inhibiting the disease or condition, i.e., preventing its development; (c) alleviating and / or ameliorating the disease or condition, i.e., causing the disease or condition to regress; or (d) curing the disease or condition, i.e., stopping its development or progression. The subject population treated by the methods of the present invention includes subjects with an undesirable condition or disease, as well as subjects at risk of developing the condition or disease.

[0019] The term "therapeutic effect" refers to some degree of alleviation of one or more symptoms of a disease (e.g., infection, neoplasia or tumor) or its associated pathology. "Therapeutically effective amount" as used herein refers to the amount of an agent that is effective in extending the survivability of a patient with such a disease, alleviating one or more signs or symptoms of the disease, preventing or delaying, etc., beyond the expected effect in the absence of such treatment, after a single dose or multiple doses are administered to a cell or object. "Therapeutically effective amount" is intended to define the amount required to achieve a therapeutic effect. A physician or veterinarian with ordinary skills in the art can easily determine and prescribe a "therapeutically effective amount" (e.g., ED50) of the desired pharmaceutical composition. For example, a physician or veterinarian can start with a dose of the vesicles of the present disclosure used in a pharmaceutical composition that is lower than the level required to achieve the desired therapeutic effect, and gradually increase the dose until the desired effect is achieved.

[0020] "Conservative amino acid substitutions" refer to substitutions of one amino acid residue for another amino acid residue that shares the chemical and physical properties (e.g., charge, size, hydrophobicity / hydrophilicity) of the amino acid side chain. "Conservative substitutions" are intended to include substitutions within the following amino acid residue groups: gly, ala; val, ile, leu; asp, glu; asn, gln; ser, thr; lys, arg and phe, tyr. Guidance for such substitutions can be obtained from alignments of amino acid sequences of polypeptides presenting an epitope of interest.

[0021] The term "heterologous" refers to two biological components that do not naturally occur together. The components can be host cells, genes, or regulatory regions, such as promoters. Although heterologous components do not naturally occur together, they can function together, such as when a promoter that is heterologous to a gene is operably linked to the gene.

[0022] The term "endogenous" refers to a naturally occurring biological component of a cell, ie, as found in nature.

[0023] As used herein, "recombinant" refers to a nucleic acid encoding a gene product, or a gene product (e.g., a polypeptide) encoded by such a nucleic acid, which has been artificially manipulated and is therefore provided in an environment or form that does not exist in nature. Thus, "recombinant" encompasses, for example, a nucleic acid encoding a gene product operably linked to a heterologous promoter (so as to provide a construct expressing a gene product from a promoter operably linked to a nucleic acid that does not exist in nature). For example, "recombinant outer membrane polypeptide" encompasses an outer membrane polypeptide encoded by a construct providing expression from a promoter heterologous to the outer membrane polypeptide encoding sequence, an outer membrane polypeptide that is modified (e.g., as in a fusion protein) relative to the naturally occurring outer membrane, etc. It should be noted that the recombinant outer membrane polypeptide can be endogenous or heterologous to the cell in which such a recombinant nucleic acid is present.

[0024] The terms "subject" and "patient" refer to an animal that is the subject of treatment, observation or experiment. By way of example only, a subject includes, but is not limited to, a mammal, including, but not limited to, a human or non-human mammal, such as a non-human primate, cow, horse, dog, sheep or cat.

[0025] Any cell, agent, vesicle, composition, or method provided herein can be combined with one or more of any other cells, agents, vesicles, compositions, and methods provided herein, whether disclosed in separate sections of the application or in the same section of the application.

[0026] Before further describing the present invention, it should be understood that the present invention is not limited to the specific embodiments described, as these embodiments may of course vary. It should also be understood that the terminology used herein is for the purpose of describing specific embodiments only and is not intended to be limiting, as the scope of the present invention will be limited only by the appended claims.

[0027] Where a range of values ​​is provided, it is understood that unless the context clearly dictates otherwise, each intervening value between the upper and lower limits of the range, up to one tenth of the unit of the lower limit, and any other specified value or intervening value within the specified range are encompassed within the present invention. The upper and lower limits of these smaller ranges may be independently included in the smaller ranges and are also encompassed within the present invention, subject to any explicitly excluded limits within the range. When the range includes one or two limits, ranges excluding one or both of those included limits are also encompassed within the present invention.

[0028] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present invention, some preferred methods and materials are now described. All publications mentioned herein are incorporated herein by reference to disclose and describe the methods and / or materials associated with the cited publications.

[0029] It must be noted that nouns as used herein and in the appended claims without quantifiers refer to one and more unless the context clearly dictates otherwise. Thus, for example, reference to a "vesicle" includes a plurality of such vesicles, and reference to a "vesicle" includes reference to one or more vesicles and equivalents thereof known to those skilled in the art, etc. It should also be noted that the claims can be drafted to exclude any optional elements. Likewise, this statement is intended to serve as an antecedent basis for the use of such exclusive terms, such as "only," "only," etc., in connection with the recitation of claim elements, or the use of a "negative" limitation.

[0030] It should be understood that, for the sake of clarity, certain features of the present invention described in the context of separate embodiments may also be provided in combination in a single embodiment. Conversely, for the sake of brevity, various features of the present invention described in the context of a single embodiment may also be provided separately or in any suitable sub-combination. All combinations of embodiments related to the present invention are specifically included in the present invention and disclosed herein, just as if each and every combination were individually and clearly disclosed. In addition, all sub-combinations of multiple embodiments and elements thereof are also specifically included in the present invention and disclosed herein, just as if each and every such sub-combination were individually and clearly disclosed herein.

[0031] The publications discussed herein only provide the disclosures prior to the filing date of the present application. Anything herein should not be construed as admitting that the present invention has no right to precede such publications. In addition, the publication date provided may be different from the actual publication date, which may require independent confirmation. DETAILED DESCRIPTION

[0032] The present disclosure provides vesicles prepared from a mammalian cell line genetically modified to overexpress a membrane protein selected from the group consisting of bifunctional heparan sulfate N-deacetylase / N-sulfotransferase 1, ferroptosis inhibitory protein 1, protein containing a cysteine-rich and transmembrane domain, cadherin-6, solute carrier family 22 member 18, promethin, receptor-type tyrosine-protein phosphatase κ, prolyl endopeptidase FAP, phospholipid transporting ATPase ID, ADP-ribosyl cyclase / cyclic ADP-ribose hydrolase 2, reticulin- 2. Ras-related protein Rap-1A, basigin, aldehyde dehydrogenase family 3 member B1, calcium homeostasis protein-1, small VCP / p97 interacting protein, GTP-binding protein Rheb, lysophosphatidic acid receptor 1, pro-low-density lipoprotein receptor-related protein 1, receptor-type tyrosine protein phosphatase F, raftlin, guanine nucleotide binding protein G(q) subunit α, guanine nucleotide binding protein subunit α-11, integrin α-8, roundabout homolog 1 1), ADP-ribosylation factor 6, ephrin B receptor 2, transforming protein RhoA, proto-oncogene tyrosine protein kinase Src, synaptic vesicle protein homolog YKT6, Ras-related protein Rab-23, vascular cell adhesion protein 1, lymphocyte function-associated antigen 3, guanine nucleotide binding protein G (I) / G (S) / G (O) subunit γ-12, 2', 3'-cyclic nucleotide 3'-phosphodiesterase, receptor-type tyrosine protein phosphatase eta, guanine nucleotide binding protein G (s) subunit alpha short isomer, ADP-ribosylation factor 5, mitochondrial calcium uniporter regulatory factor 1, nuclear mitotic apparatus protein 1, protein / nucleic acid deglycosylase DJ-1, T cell activation inhibitor containing V-type immunoglobulin domain, CD276, MCAM and phosphatidylserine synthase 2. Genetically modified cells are also provided. The vesicles can be used in a method of reducing inflammatory response in a subject in need thereof. Vesicles and compositions thereof

[0033] Disclosed are vesicles prepared by cells that overexpress one or more membrane proteins, which are identified herein as those associated with the anti-inflammatory properties of vesicles prepared from human mesenchymal stem cells (MSCs). As described in the Examples section, EV, NV, and SyEV prepared from MSCs have anti-inflammatory activity. By comparing the proteomes of these three types of vesicles, membrane proteins with relatively similar levels in these three types of vesicles were identified. These membrane proteins are likely to contribute to the anti-inflammatory properties of these vesicles. Membrane proteins that differed less than 1.5-fold between the three types of vesicles included: bifunctional heparan sulfate N-deacetylase / N-sulfotransferase 1, ferroptosis inhibitory protein 1, protein containing cysteine-rich and transmembrane domains, cadherin-6, solute carrier family 22 member 18, promethin, receptor-type tyrosine protein phosphatase κ, prolyl endopeptidase FAP, phospholipid transporter ATPase ID, ADP-ribosyl cyclase / cyclic ADP-ribose hydrolase 2, reticulin-2, ras-related protein Rap-1A, basigin, aldehyde dehydrogenase family 3 member B1, calcium homeostasis protein-1, small VCP / p97 interacting protein, GTP-binding protein Rheb, lysophosphatidic acid receptor 1, pro-low-density lipoprotein receptor-related protein 1, receptor-type tyrosine protein phosphatase F, raftlin, guanine Nucleotide-binding protein G(q) subunit alpha, guanine nucleotide-binding protein subunit alpha-11, integrin alpha-8, circular cross-linked axon guidance receptor homolog 1, ADP-ribosylation factor 6, ephrin B receptor type 2, transforming protein RhoA, proto-oncogene tyrosine-protein kinase Src, synaptic vesicle protein homolog YKT6, Ras-related protein Rab-23, vascular cell adhesion protein 1, lymphocyte function-associated antigen 3, guanine nucleotide-binding protein G(I) / G(S) / G(O) subunit gamma-12, 2',3'-cyclic nucleotide 3'-phosphodiesterase, receptor-type tyrosine-protein phosphatase eta, guanine nucleotide-binding protein G(s) subunit alpha short isoform, ADP-ribosylation factor 5, mitochondrial calcium uniporter regulatory factor 1, nuclear mitotic apparatus protein 1, protein / nucleic acid deglycosylase DJ-1. In addition, membrane proteins present at levels less than 1.5-fold different between any two of the three types of vesicles are also likely to be required for the anti-inflammatory properties of these vesicles. Such membrane proteins include V-type immunoglobulin domain-containing inhibitor of T-cell activation, CD276, MCAM, and phosphatidylserine synthase 2.

[0034] In certain aspects, the vesicles are prepared from a mammalian cell line genetically modified to overexpress a membrane protein, wherein the membrane protein is selected from: bifunctional heparan sulfate N-deacetylase / N-sulfotransferase 1, ferroptosis inhibitory protein 1, protein containing cysteine-rich and transmembrane domains, cadherin-6, solute carrier family 22 member 18, promethin, receptor-type tyrosine protein phosphatase κ, prolyl endopeptidase FAP, phospholipid transporting ATPase ID, ADP-ribosyl cyclase / cyclic ADP-ribose hydrolase 2, reticulin-2, ras-related protein Rap-1A, basigin, aldehyde dehydrogenase family 3 member B1, calcium homeoprotein-1, small VCP / p97 interacting protein, GTP-binding protein Rheb, lysophosphatidic acid receptor 1, pre-low-density lipoprotein receptor-related protein 1, receptor-type tyrosine protein phosphatase F, raftlin, guanine nucleotide binding protein G(q) subunit α, guanine nucleotide binding protein subunit α-11, integrin α-8, circular cross-linked axon guidance receptor homolog 1, ADP-ribosylation factor 6, ephrin type B receptor 2, transforming protein RhoA, proto-oncogene tyrosine protein kinase Src, synaptic vesicle protein homolog YKT6, Ras-related protein Rab-23, vascular cell adhesion protein 1, lymphocyte function-associated antigen 3, guanine nucleotide binding protein G(I) / G(S) / G(O ) subunit γ-12, 2',3'-cyclic nucleotide 3'-phosphodiesterase, receptor-type tyrosine protein phosphatase eta, guanine nucleotide binding protein G (s) subunit alpha short isomer, ADP-ribosylation factor 5, mitochondrial calcium uniporter regulatory factor 1, nuclear mitotic apparatus protein 1, protein / nucleic acid deglycosylase DJ-1, T cell activation inhibitor containing V-type immunoglobulin domain, CD276, MCAM and phosphatidylserine synthase 2. A composition is also provided, which comprises a vesicle; and a pharmaceutically acceptable carrier. The vesicle reduces the level of at least one proinflammatory cytokine in the subject when administered to the subject.

[0035] In some aspects, the mammalian cell line from which the vesicles are prepared is genetically modified to contain an exogenous nucleic acid sequence encoding a membrane protein. In some aspects, the exogenous nucleic acid sequence is operably linked to a heterologous promoter. In other aspects, the exogenous nucleic acid sequence is operably linked to an endogenous promoter. In some aspects, the mammalian cell line from which the vesicles are prepared is genetically modified to increase the expression of an endogenous gene encoding a membrane protein. For example, by introducing a transcriptional activator of an endogenous gene or by inserting a heterologous promoter into an endogenous gene, wherein the heterologous promoter provides increased expression of the endogenous gene.

[0036] In certain aspects, the mammalian cell line from which the vesicles are produced can be genetically modified to overexpress at least two membrane proteins identified herein. In certain aspects, the mammalian cell line from which the vesicles are produced can be genetically modified to overexpress three or more membrane proteins.

[0037] In certain aspects, the composition comprising vesicles may comprise a first population of vesicles prepared from a first mammalian cell line genetically modified to overexpress a first membrane protein and a second population of vesicles prepared from a second mammalian cell line genetically modified to overexpress a second membrane protein, wherein the first membrane protein and the second membrane protein are independently selected from: bifunctional heparan sulfate N-deacetylase / N-sulfotransferase 1, ferroptosis inhibitory protein 1, protein containing cysteine-rich and transmembrane domains, cadherin-6, solute carrier family 22 members 18, promethin, receptor-type tyrosine protein phosphatase kappa, prolyl endopeptidase FAP, phospholipid transport ATPase ID, ADP-ribosyl cyclase / cyclic ADP-ribose hydrolase 2, reticulin-2, ras-related protein Rap-1A, basigin, aldehyde dehydrogenase family 3 member B1, calcium homeoprotein-1, small VCP / p97 interacting protein, GTP-binding protein Rheb, lysophosphatidic acid receptor 1, pro-low-density lipoprotein receptor-related protein 1, receptor-type tyrosine Acid protein phosphatase F, raftlin, guanine nucleotide binding protein G (q) subunit α, guanine nucleotide binding protein subunit α-11, integrin α-8, circular cross-linked axon guidance receptor homolog 1, ADP-ribosylation factor 6, ephrin B receptor type 2, transforming protein RhoA, proto-oncogene tyrosine protein kinase Src, synaptic vesicle protein homolog YKT6, Ras-related protein Rab-23, vascular cell adhesion protein 1, lymphocyte function-associated antigen 3, guanine nucleotide binding , 2',3'-cyclic nucleotide 3'-phosphodiesterase, receptor-type tyrosine protein phosphatase eta, guanine nucleotide binding protein G (s) subunit alpha short isoform, ADP-ribosylation factor 5, mitochondrial calcium uniporter regulatory factor 1, nuclear mitotic apparatus protein 1, protein / nucleic acid deglycosylase DJ-1, V-type immunoglobulin domain-containing T cell activation inhibitor, CD276, MCAM and phosphatidylserine synthase 2. In some aspects, the composition may further include a third population of vesicles prepared by a third mammalian cell line genetically modified to overexpress a third membrane protein selected from the listed membrane proteins, wherein the third protein is different from the first protein and the second protein. In some aspects, the composition may further include a fourth population of vesicles prepared by a fourth mammalian cell line genetically modified to overexpress a fourth membrane protein selected from the listed membrane proteins, wherein the fourth protein is different from the first protein, the second protein and the third protein. One or more mammalian cell lines used to prepare the vesicle population can be further genetically modified to overexpress more than one of the listed membrane proteins.

[0038] The genetically modified mammalian cell line can be a mammalian cell line produced by a parental cell, wherein the parental cell is a mammalian cell line or a primary cell. The mammalian cell line can be a HEK293 cell line, a CHO cell line or an embryonic stem cell line. The primary cell can be a stem cell separated from a subject. In some aspects, the primary cell can be autologous to the subject. In some aspects, the stem cell can be an embryonic stem cell, an induced pluripotent stem cell, a hematopoietic stem cell, a neuronal stem cell, a mesenchymal stem cell, a muscle stem cell or a skin stem cell.

[0039] In certain aspects, a mammalian cell genetically modified to overexpress a membrane protein as disclosed herein may express the protein at a level that is 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, or 10 times higher or more than the level expressed in the unmodified parental cell from which the genetically modified mammalian cell line was derived.

[0040] In certain aspects, the vesicles of the present disclosure obtained from mammalian cells genetically modified to overexpress a membrane protein disclosed herein contain a level of a membrane protein that is 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, or 10 times or more higher than the level expressed in vesicles from the unmodified parental cells from which the genetically modified mammalian cell line was generated. For example, the SyEVs of the present disclosure express the bifunctional heparan sulfate N-deacetylase / N-sulfotransferase 1 at a level that is 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, or 10 times or more higher than the level expressed in SyEVs produced from the unmodified parental cells from which the genetically modified mammalian cell line was generated.

[0041] In certain aspects, the vesicles of the present disclosure are roughly spherical and their size (e.g., diameter or largest dimension) can be in the range of 10nm to 200nm, e.g., 20nm to 200nm, 30nm to 200nm, 40nm to 200nm, 50nm to 200nm, 30nm to 175nm, 30nm to 150nm, 40nm to 175nm, or 50nm to 150nm.

[0042] As used herein, "bifunctional heparan sulfate N-deacetylase / N-sulfotransferase 1" encompasses naturally occurring and synthetic (non-naturally occurring) polypeptides that share at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or more sequence identity with naturally occurring bifunctional heparan sulfate N-deacetylase / N-sulfotransferase 1 at the nucleotide or amino acid level. "Bifunctional heparan sulfate N-deacetylase / N-sulfotransferase 1" also encompasses fusion proteins, such as bifunctional heparan sulfate N-deacetylase / N-sulfotransferase 1 with a heterologous polypeptide at the N-terminus and / or C-terminus. In certain aspects, the naturally occurring bifunctional heparan sulfate N-deacetylase / N-sulfotransferase 1 is a protein identified with UniProt Acc. No. P52848.

[0043] As used herein, "ferroptosis inhibitory protein 1" encompasses naturally occurring and synthetic (non-naturally occurring) polypeptides that share at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or higher sequence identity with naturally occurring ferroptosis inhibitory protein 1 at the nucleotide or amino acid level. "Ferroptosis inhibitory protein 1" also encompasses fusion proteins, such as bifunctional heparan sulfate N-deacetylase / N-sulfotransferase 1 with a heterologous polypeptide at the N-terminus and / or C-terminus. In certain aspects, the naturally occurring ferroptosis inhibitory protein 1 is a protein identified with UniProt Acc. No. Q9BRQ8.

[0044] As used herein, "protein 1 containing rich cysteine ​​and transmembrane domains" encompasses naturally occurring and synthetic (non-naturally occurring) polypeptides that share at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or higher sequence identity with naturally occurring protein 1 containing rich cysteine ​​and transmembrane domains at the nucleotide or amino acid level. "Protein 1 containing rich cysteine ​​and transmembrane domains" also encompasses fusion proteins, such as bifunctional heparan sulfate N-deacetylase / N-sulfotransferase 1 with a heterologous polypeptide at the N-terminus and / or C-terminus. In certain aspects, naturally occurring protein 1 containing rich cysteine ​​and transmembrane domains is a protein identified with UniProt Acc. No. Q9H1C7.

[0045] As used herein, "Cadherin-6" encompasses naturally occurring and synthetic (non-naturally occurring) polypeptides that share at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or higher sequence identity with naturally occurring Cadherin-6 at the nucleotide or amino acid level. "Cadherin-6" also encompasses fusion proteins, such as Cadherin-6 with a heterologous polypeptide at the N-terminus and / or C-terminus. In some aspects, naturally occurring Cadherin-6 is a protein identified with UniProt Acc. No. P55285.

[0046] As used herein, "solute carrier family 22 member 18" encompasses naturally occurring and synthetic (non-naturally occurring) polypeptides that share at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or more sequence identity at the nucleotide or amino acid level with the naturally occurring solute carrier family 22 member 18. "Solute carrier family 22 member 18" also encompasses fusion proteins, such as solute carrier family 22 member 18 with a heterologous polypeptide at the N-terminus and / or C-terminus. In certain aspects, the naturally occurring solute carrier family 22 member 18 is a protein identified with UniProt Acc. No. Q96BI1.

[0047] As used herein, "lipid droplet assembly factor 1" encompasses naturally occurring and synthetic (non-naturally occurring) polypeptides that share at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or higher sequence identity with naturally occurring lipid droplet assembly factor 1 at the nucleotide or amino acid level. "Lipid droplet assembly factor 1" also encompasses fusion proteins, such as lipid droplet assembly factor 1 with a heterologous polypeptide at the N-terminus and / or C-terminus. In certain aspects, the naturally occurring lipid droplet assembly factor 1 is a protein identified with UniProt Acc. No. Q96B96.

[0048] As used herein, "MAP kinase activated death domain protein" encompasses naturally occurring and synthetic (non-naturally occurring) polypeptides that share at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or more sequence identity with a naturally occurring MAP kinase activated death domain protein at the nucleotide or amino acid level. "MAP kinase activated death domain protein" also encompasses fusion proteins, such as MAP kinase activated death domain proteins with heterologous polypeptides at the N-terminus and / or C-terminus. In certain aspects, the naturally occurring MAP kinase activated death domain protein is a protein identified with UniProtAcc.No.Q8WXG6.

[0049] As used herein, "receptor tyrosine protein phosphatase κ" encompasses naturally occurring and synthetic (non-naturally occurring) polypeptides that share at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or higher sequence identity with naturally occurring receptor tyrosine protein phosphatase κ at the nucleotide or amino acid level. "Receptor tyrosine protein phosphatase κ" also encompasses fusion proteins, such as receptor tyrosine protein phosphatase κ with a heterologous polypeptide at the N-terminus and / or C-terminus. In certain aspects, the naturally occurring receptor tyrosine protein phosphatase κ is a protein identified with UniProt Acc. No. Q15262.

[0050] As used herein, "prolyl endopeptidase FAP" encompasses naturally occurring and synthetic (non-naturally occurring) polypeptides that share at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or higher sequence identity with naturally occurring prolyl endopeptidase FAP at the nucleotide or amino acid level. "Prolyl endopeptidase FAP" also encompasses fusion proteins, such as prolyl endopeptidase FAP with a heterologous polypeptide at the N-terminus and / or C-terminus. In certain aspects, the naturally occurring prolyl endopeptidase FAP is a protein identified with UniProt Acc. No. Q12884.

[0051] As used herein, "phospholipid transport ATPase ID" encompasses naturally occurring and synthetic (non-naturally occurring) polypeptides that share at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or higher sequence identity with a naturally occurring phospholipid transport ATPase ID at the nucleotide or amino acid level. "Phospholipid transport ATPase ID" also encompasses fusion proteins, such as phospholipid transport ATPase IDs with heterologous polypeptides at the N-terminus and / or C-terminus. In certain aspects, the naturally occurring phospholipid transport ATPase ID is a protein identified with UniProt Acc. No. P98198.

[0052] As used herein, "T cell activation inhibitors containing V-type immunoglobulin domains" encompass naturally occurring and synthetic (non-naturally occurring) polypeptides that share at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or higher sequence identity with naturally occurring T cell activation inhibitors containing V-type immunoglobulin domains at the nucleotide or amino acid level. "T cell activation inhibitors containing V-type immunoglobulin domains" also encompass fusion proteins, such as T cell activation inhibitors containing V-type immunoglobulin domains with heterologous polypeptides at the N-terminus and / or C-terminus. In certain aspects, the naturally occurring T cell activation inhibitor containing V-type immunoglobulin domains is a protein identified with UniProt Acc. No. Q9H7M9.

[0053] As used herein, "CD276" encompasses naturally occurring and synthetic (non-naturally occurring) polypeptides that share at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or higher sequence identity with naturally occurring CD276 at the nucleotide or amino acid level. "CD276" also encompasses fusion proteins, such as CD276 with a heterologous polypeptide at the N-terminus and / or C-terminus. In certain aspects, naturally occurring CD276 is a protein identified with UniProt Acc. No. Q5ZPR3.

[0054] As used herein, "MCAM" encompasses naturally occurring and synthetic (non-naturally occurring) polypeptides that share at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or more sequence identity with naturally occurring MCAM at the nucleotide or amino acid level. "MCAM" also encompasses fusion proteins, such as MCAM with a heterologous polypeptide at the N-terminus and / or C-terminus. In certain aspects, naturally occurring MCAM is a protein identified with UniProt Acc. No. P43121.

[0055] As used herein, "phosphatidylserine synthase 2" encompasses naturally occurring and synthetic (non-naturally occurring) polypeptides that share at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or more sequence identity with naturally occurring phosphatidylserine synthase 2 at the nucleotide or amino acid level. "Phosphatidylserine synthase 2" also encompasses fusion proteins, such as phosphatidylserine synthase 2 with a heterologous polypeptide at the N-terminus and / or C-terminus. In certain aspects, the naturally occurring phosphatidylserine synthase 2 is a protein identified with UniProt Acc. No. Q9BVG9.

[0056] The percent identity between a pair of sequences can be calculated by multiplying the number of matches in the pair by 100 and dividing by the length of the aligned region (including gaps). The identity score only counts perfect matches and does not take into account how similar the amino acids are to each other. Only internal gaps are included in the length, not gaps at the ends of the sequence.

[0057] Percent identity = (match x 100) / length of the alignment region (with gaps)

[0058] Guidance for substitution, insertion or deletion can be based on alignment of amino acid sequences of proteins from different species, or from alignment of consensus sequences of multiple proteins having the same or similar function.

[0059] In certain aspects, a composition comprising a vesicle and a pharmaceutically acceptable carrier is provided. The carrier can be a diluent, a carrier, an excipient, a salt, a buffer, an antioxidant (e.g., ascorbic acid and sodium bisulfate), a preservative (e.g., benzyl alcohol, methyl parahydroxybenzoate, ethyl parahydroxybenzoate or n-propyl parahydroxybenzoate), an emulsifier, a suspending agent, a dispersant, a solvent, a filler, a filler, a detergent and / or an adjuvant. For example, a suitable carrier can be a physiological saline solution or a buffered saline solution, which may be supplemented with other substances commonly used in pharmaceutical compositions for, for example, parenteral administration. Neutral buffered saline or saline mixed with serum albumin is another exemplary carrier. Those skilled in the art will readily recognize that a variety of buffers can be used in the composition. Typical buffers include, but are not limited to, pharmaceutically acceptable weak acids, weak bases, or mixtures thereof. As an example, a buffer component can be a water-soluble substance, such as phosphoric acid, tartaric acid, lactic acid, succinic acid, citric acid, acetic acid, ascorbic acid, aspartic acid, glutamic acid, and salts thereof. Acceptable buffers include, for example, Tris buffer, N-(2-hydroxyethyl)piperazine-N'-(2-ethanesulfonic acid) (HEPES), 2-(N-morpholino)ethanesulfonic acid (MES), 2-(N-morpholino)ethanesulfonic acid sodium salt (MES), 3-(N-morpholino)propanesulfonic acid (MOPS) and N-tris[hydroxymethyl]methyl-3-aminopropanesulfonic acid (TAPS). In certain aspects, the excipients included in the disclosed compositions can be polyICLC, 1018ISS, aluminum salts, Amplivax, AS15, BCG, CP-870,893, CpG7909, CyaA, dSLIM, GM-CSF, IC30, IC31, Imiquimod, ImuFact IMP321, ISPatch, ISS, ISCOMATRIX, Juvlmmune, LipoVac, MF59, monophosphoryllipid-A (MPL), Montanide IMS1312, Montanide ISA 206, Montanide ISA 50V, MontanideISA-51, OK-432, OM-174, OM-197-MP-EC, ONTAK, PEPTEL, carrier system, PLGA microparticles, resiquimod, SRL172, virosomes and other virus-like particles, YF-17D, VEGF trap, R848, β-glucan, Pam3Cys, acrylic acid polymer or methacrylic acid polymer, or copolymers of maleic anhydride and Aquila's QS21 stimulon.

[0060] Also provided herein are genetically modified mammalian cell lines as disclosed above. In some aspects, the mammalian cell can be an autologous mammalian cell. The autologous cell can be derived from a tissue or organ of the subject. In some aspects, the mammalian cell can be a heterologous mammalian cell. In some aspects, the heterologous mammalian cell can be derived from a tissue or organ of a donor, or from a cell line. The tissue or organ from which the mammalian cell is derived can be bone marrow, blood, blood products, adipose tissue, umbilical cord blood, fallopian tube, liver, fetal liver or fetal lung, etc. In some aspects, the mammalian cell can be a monocyte, a macrophage or a dendritic cell.

[0061] In some aspects, the mammalian cell can be a stem cell. In some aspects, the mammalian cell can be a cell line, such as an embryonic stem cell line, an induced pluripotent stem cell line, or any other cell line. In some aspects, the stem cell can be an embryonic stem cell or a somatic stem cell, such as an embryonic stem cell or a somatic stem cell present in children and adults. In some aspects, the mammalian cell can be a hematopoietic stem cell, a mammary stem cell, an intestinal stem cell, an endothelial stem cell, a neural stem cell, an olfactory stem cell, a neural crest stem cell, or a testicular stem cell. In some aspects, the mammalian cell can be a mesenchymal stem cell.

[0062] In certain aspects, the mammalian cell can be a cell that is naturally produced or further genetically modified to produce one or more therapeutic agents, such as trophic factors, such as CDNF, GDNF, neurotrophin, IGF1, VEGF, HGF; molecular chaperones, such as HSP104, HSP70; ephA4; ephA4 ligand; Poly (A) Binding Protein Nuclear 1 (PABPN1); matrix protein ubiquilin-related progeroid protein 2 (matrin ubiquilin 2); zinc finger protein 106 (ZFP 106); IRE1α kinase / RNA enzyme; ubiquitin-related progeroid protein; TANK Binding Kinase 1 (TBK1); MuSK agonist antibody; Ankyrin Repeat And KH Domain Containing 1 (Ankyrin Repeat And KH Domain Containing 1, ANKHD1); affitin; Glycerophosphodiesterphosphodiesterase 2 (GDE2); MMIF; SRSF1 nuclear translocation; anti-mir155; miRNA 125b; miRNA31; miRNA-206; miRNA133b; TREM2 activating antibody; SARM1 inhibitor; macrophage migration inhibitory factor (MIF); dominant negative NFkB; muscle-specific kinase; siRNA targeting tristetraprolin; PPARγ coactivator 1α; Ret receptor; notch intracellular domain; TGFβ; INFγ, etc. Vesicle production

[0063] The vesicles of the present disclosure can be any type of vesicle, such as EVs naturally released from cells, or vesicles generated from extruding cells or by opening cells and re-vesiculating the cell membrane.

[0064] In certain aspects, EVs are isolated from cell culture supernatants of genetically modified cells provided herein. For example, the cell culture supernatant may be centrifuged to remove cell debris. The resulting supernatant may be ultracentrifuged to separate large vesicles and small vesicles. The supernatant may be centrifuged at 16,500 × g for about 20 minutes to collect large vesicles, and at 120,000 × g for about 2.5 hours to collect small vesicles, at 4 ° C. Small vesicles (e.g., 40nm to 100nm in diameter) may be further purified by using density gradient centrifugation.

[0065] In certain aspects, NVs and SyEVs can be prepared from genetically modified cells provided herein by performing the following: disrupting mammalian cells to produce vesicles; separating the vesicles based on density and isolating NVs; exposing the isolated nanovesicles to an alkaline pH to open the nanovesicles, thereby producing plasma membrane sheets; purifying the plasma membrane sheets; and applying energy to the purified plasma membrane sheets sufficient to convert the plasma membrane sheets into SyEVs.

[0066] In some aspects, the method may include adding a therapeutic agent to a composition comprising purified membrane sheets, and applying energy to the composition sufficient to convert the plasma membrane sheets into SyEVs comprising the therapeutic agent. In some aspects, the therapeutic agent does not include an anti-inflammatory agent. In some aspects, the SyEVs do not include a significant amount of an anti-inflammatory agent, for example, the SyEVs may include trace amounts of an anti-inflammatory agent. In some aspects, the composition comprising the SyEVs is substantially free of an anti-inflammatory agent.

[0067] In some aspects, destroying mammalian cells to produce vesicles may involve mechanical, electrical or chemical methods for cell lysis. Some examples of techniques for cell lysis include infiltration, electroporation, sonication, homogenization, detergent treatment, freeze-thaw, extrusion, mechanical degradation and chemical treatment, but are not limited thereto. In some aspects, mammalian cells are not destroyed by detergent treatment. In the mechanical degradation method, the mammalian cell solution is shaken with a metal, ceramic or sufficiently hard plastic ball. In some aspects, destroying mammalian cells may include applying shear force to the mammalian cells. Shear force may be applied by extruding the mammalian cells. Extrusion may include forcing the mammalian cells to pass through a hole smaller than the size of the mammalian cells. In the case of extrusion, the mammalian cells may be forced to pass through a series of filters with gradually decreasing pore sizes. For example, mammalian cells pass through three filters with pore sizes of 10 μm → 5 μm → 1 μm in sequence to form vesicles.

[0068] In some aspects, destroying mammalian cells may include applying acoustic energy to the mammalian cells. The acoustic energy may be applied by an acoustic treatment device. The acoustic conditions may be adjusted according to the desired destruction energy. For example, when destroying the cell membrane to produce vesicles, low temperature, low energy and / or short duration may be used for acoustic treatment. The acoustic treatment may be performed with different intensities, including low energy acoustic treatment for a period of 1 minute to 3 hours. In some aspects, an ultrasonic probe type device may be used for acoustic treatment. In some aspects, an ultrasonic bath may be used for acoustic treatment. The duration of acoustic treatment may be adjusted according to the type of device used to perform the acoustic treatment. For example, an ultrasonic probe type device may provide energy that is about 1000 times higher than an ultrasonic bath. In some aspects, an ultrasonic probe type device may be used to destroy mammalian cells.

[0069] After disrupting mammalian cells to produce vesicles (e.g., vesicles having a plasma membrane encapsulating cytoplasmic contents), these vesicles can be isolated from any remaining mammalian cells. Isolation of these vesicles from mammalian cells can be performed using differences in size, density, buoyancy, etc. In certain aspects, centrifugation (e.g., density gradient centrifugation or density gradient ultracentrifugation) or filtration can be performed to separate vesicles. In certain aspects, density gradient ultracentrifugation can be used to purify vesicles, wherein vesicles present at a density gradient of 10% to 50% can be isolated. Vesicles present at a density gradient of 10% to 50% are mostly nano-sized vesicles or nanovesicles.

[0070] The separated nanovesicles can then be exposed to an alkaline solution to open the nanovesicles, thereby expelling the cytoplasmic contents of the nanovesicles. In certain aspects, the pH of the alkaline solution used to open the nanovesicles can be 11 to 14. The alkaline solution used to open the nanovesicles can be prepared from sodium carbonate (Na2CO3), sodium hydroxide (NaOH), ammonia (NH3), calcium hydroxide (Ca(OH)2), potassium hydroxide (KOH), sodium bicarbonate (NaHCO3) or magnesium hydroxide (Mg(OH)2) solution. The incubation duration of the nanovesicles in the alkaline solution can be adjusted based on the number of nanovesicles, the total volume of the solution, etc. The step of incubating or exposing the vesicles to an alkaline pH used herein can include using an alkaline solution having a pH of 9 to 14, such as a pH of 10 to 14, a pH of 11 to 14, a pH of 12 to 14, or a pH of 13 to 14.

[0071] By using any suitable separation method, the plasma membrane sheet produced by opening the nanovesicle can be separated from the whole nanovesicle (i.e., unopened). In some aspects, the plasma membrane sheet can be purified by centrifugation, such as centrifugation (e.g., density gradient centrifugation or density gradient ultracentrifugation), filtration, or another suitable method, such as size exclusion, dialysis, tangential flow filtration, etc. In some aspects, density gradient ultracentrifugation can be used to purify the plasma membrane sheet, wherein the plasma membrane sheet present in a density gradient of 10% to 30% can be separated. The plasma membrane sheet present in a density gradient of 10% to 30% is substantially free of nanovesicles.

[0072] In some aspects, the method of producing SyEV may involve applying energy or force sufficient to convert the plasma membrane sheet into SyEV to the purified plasma membrane sheet. Suitable energy sources include gentle sonication, shear force, acoustic force, freeze-thaw, etc. In some aspects, the purified plasma membrane sheet can be sonicated for a duration sufficient to convert the plasma membrane sheet into SyEV. In some aspects, the purified plasma membrane sheet can be sonicated by applying an energy that is 1 / 100 to 1 / 1000 of the energy applied to destroy mammalian cells. In some aspects, gentle sonication may include using an ultrasonic bath to convert the plasma membrane sheet into SyEV.

[0073] In certain aspects, the vesicles of the present disclosure can be Figure 1 Prepared by the method shown in .

[0074] The term "lack" used in the context of a component present in a ghost nanovesicle or synthetic nanovesicle (gNV or SyEV) derived from a cell as disclosed herein means that the component is at least 50% less, such as 60%, 70%, 80%, 90% or 99% less than the amount of the component present in a non-ghost nanovesicle produced by the same cell. The terms gNV and SyEV are used interchangeably herein. Vesicles that are not prepared by opening and closing vesicles are referred to as nanovesicles.

[0075] The term "enriched" as used in the context of a protein (e.g., a membrane protein) present in SyEVs derived from cells as disclosed herein means that the component makes up a larger portion of the total amount of protein in the SyEVs than the portion of the same protein in NVs produced from the same cell type. For example, the enriched protein may make up at least 25% or more of the total protein in the SyEVs, while the same protein may make up at most 20% of the total protein in the NVs. The enriched component may be present in the SyEVs at a higher concentration by total weight, for example, at a concentration that is at least three times higher by total weight than the concentration of the component by total weight in NVs produced from the same cell type from which the SyEVs are derived, for example, at least 5 times higher concentration, at least 10 times higher concentration, at least 30 times higher concentration, at least 50 times higher concentration, or at least 100 times higher concentration.

[0076] The SyEV provided herein retains a membrane protein that is essentially in a native conformation. For example, during the production of SyEV, SyEV is not exposed to a denaturant used as a vesicle forming agent. For example, the method for preparing SyEV does not include a step of exposing mammalian cells to a vesicle forming agent to form vesicles. In other words, during or after the production of SyEV, SyEV is not exposed to a vesicle forming agent, such as a sulfhydryl blocking agent, so that SyEV maintains the membrane protein in its native conformation. SyEV is not exposed to vesicle forming agents, such as formaldehyde and dithiothreitol, during or after formation. Thiol blocking agents include formaldehyde, acetaldehyde, glyoxal, glutaraldehyde, acrolein, methacrolein, pyridoxal, N-ethyl maleimide (NEM), maleimide, chloromercuric benzoate, iodoacetate, potassium arsenite, sodium selenite, thimerosal (merthiolate), benzoyl peroxide, cadmium chloride, hydrogen peroxide, iodobenzoic acid, meralluride sodium

[0063] In some embodiments, the present invention relates to mercuric chloride, mercurous chloride, chlormerodrin (neohydrin), phenylhydrazine, potassium tellurite, sodium malonate, p-arsenylbenzoic acid, 5,5'-diamino-2,2'-dimethylarsinylbenzene, N,N'-dimethylmethylenesulfonic acid disodium salt, iodoacetamide, oxophenylarsine (mapharsen), gold chloride, p-chloromercuric benzoic acid, p-chloromercuric benzenesulfonic acid, cupric chloride, iodine mercurochrome (mercurochrome) porphyrin, potassium permanganate, salyrgan, silver nitrate, protargol, uranyl acetate, etc. Other examples of vesicle forming agents include cytotoxins such as cytochalasin B or melittin.

[0077] SyEV may be roughly spherical in shape and may have a smaller diameter than the cells producing SyEV. In some aspects, SyEV may be a relatively large SyEV, and its diameter may range from 100nm to 900nm, for example, 100nm to 800nm, 100nm to 700nm, 100nm to 600nm, 100nm to 500nm, 100nm to 400nm, 100nm to 300nm or 100nm to 200nm. In some aspects, SyEV may be a relatively small SyEV, and its diameter may range from 10nm to 100nm, for example, 20nm to 100nm, 30nm to 100nm or 40nm to 100nm. In some aspects, the preparation of SyEV, such as the composition of SyEV may include large SyEV and small SyEV.

[0078] SyEV can be formed by opening nanovesicles (NV), for example, by exposing NV to high pH, ​​separating open cell membrane sheets, and closing open cell membrane sheets to produce SyEV. In some aspects, gNV can be formed by: destroying mammalian cells to produce vesicles; using density gradients to separate vesicles and separate nanovesicles; exposing isolated nanovesicles to alkaline pH to open nanovesicles to produce plasma membrane sheets; purifying plasma membrane sheets; and applying energy sufficient to convert plasma membrane sheets into SyEV to purified plasma membrane sheets. NV formed by such a method comprises cytoplasmic components, such as organelles, cytoplasmic proteins, nuclei, nucleic acids (e.g., RNA, such as mRNA, miRNA, etc.). gNV lacks such a component, that is, the component is at least 50% less, for example, 60%, 70%, 80%, 90% or 99% less than the amount of the component present in NV.

[0079] In certain aspects, SyEVs are prepared by adding a therapeutic agent to a composition comprising purified membrane sheets, and applying energy to the composition sufficient to convert the plasma membrane sheets into SyEVs comprising the therapeutic agent. In certain aspects, the therapeutic agent does not comprise an anti-inflammatory agent.

[0080] In some aspects, SyEV can be loaded with a therapeutic agent, which is a nucleic acid, a peptide or a protein. The therapeutic agent can be an antibody, a growth factor (e.g., EGF, FGF, VEGF, etc.), siRNA, miRNA, shRNA, etc. In some aspects, the therapeutic agent can be an anticancer agent or an angiogenesis inhibitor. In certain aspects, the anticancer agent can be a DNA alkylating agent, such as mechlorethamine, chlorambucil, phenylalanine, mustard, cyclophosphamide, ifosfamide, carmustine (BCNU), lomustine (CCNU), streptozotocin, busulfan, thiotepa, cisplatin and carboplatin, an anticancer antibiotic, such as actinomycin D, adriamycin, epirubicin, idarubicin, mitoxantrone, plicamycin, mitomycin C, C) and bleomycin, and plant alkaloids such as vincristine, vinblastine, paclitaxel, docetaxel, daunorubicin, taxol, oncovin, prednisone, cisplatin, herceptin, rituximab, etoposide, teniposide, topotecan, and irinotecan. method

[0081] In certain aspects, methods for treating a subject in need thereof are provided. In certain aspects, methods for reducing inflammation in a subject in need thereof are provided. The method may comprise administering to the subject an effective amount of a vesicle disclosed herein, wherein the vesicle reduces the level of at least one pro-inflammatory cytokine in the subject.

[0082] The term "reduced" in the context of an inflammatory response means that lower levels of proinflammatory cytokines are produced after administration of the vesicles compared to the proinflammatory cytokines produced in the absence of the vesicles. In some embodiments, the production of cytokines is reduced by at least 5%, for example, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60% or more compared to the cytokines produced in the absence of the administration of the vesicles. The at least one proinflammatory cytokine may include one or more of IL-2, IL-4, IL-6, IL-12, IL-12p70, IL-17, tumor necrosis factor alpha (TNF-α), or interferon gamma (IFN-γ). The mammalian cell from which the vesicle is derived can be as described in the vesicle description of the disclosure provided in the previous section.

[0083] The subject in need of reducing inflammation may suffer from or be susceptible to an inflammatory-related disorder. The inflammatory-related disorder may be cancer, multiple sclerosis, psoriasis, dry eye, asthma, sepsis, infection, rheumatoid arthritis, ulcerative colitis, Crohn's disease, tuberculosis, hepatitis, sinusitis, autoimmune disease, inflammatory bowel disease, pelvic inflammatory disease, ulcer, atherosclerosis, erythema, necrosis, vasculitis, ankylosing spondylitis, connective tissue disease, kidney disease, sarcoidosis, thyroiditis, osteoarthritis, rheumatism, chronic inflammatory disorders, demyelinating polyneuropathy, pancreatitis, psoriatic arthritis, periodontitis, Behcet's disease, sinusitis, polymyalgia rheumatica, nephritis, diverticulitis, granulomatosis polyangiitis, In some aspects, the inflammatory-related disorder may be asthma. In some aspects, the inflammatory-related condition can be sepsis. In some aspects, the inflammatory-related condition can be infection. In some aspects, the inflammatory-related condition can be a bacterial, viral or parasitic infection.

[0084] In some aspects, the method of reducing inflammation may include administering an additional therapeutic agent to the subject. In some aspects, the additional therapeutic agent is present in a vesicle. In some aspects, the method includes administering a composition comprising an additional therapeutic agent and a vesicle. In some aspects, the method includes administering an additional therapeutic agent associated with the vesicle, such as co-administering (as a single composition or substantially simultaneously) or sequentially administering the vesicle and the additional therapeutic agent.

[0085] The therapeutic agent can be a small molecule, a peptide, a nucleic acid or a polypeptide. The therapeutic agent can be as provided in the preceding section. The therapeutic agent can have general anti-inflammatory properties, or can target different stages (steps) of the inflammatory pathway in the cell, such as downstream TLR receptor activation (Myd88 or NFKB), cytokine receptor downstream or interferon gene stimulator (Stimulator ofInterferon Gens, STING) pathway. Vesicle administration

[0086] The present disclosure contemplates administration of the disclosed compositions in any suitable manner for preventing and / or treating conditions as described herein. Suitable routes of administration include parenteral (e.g., intramuscular, intravenous, intraarterial, subcutaneous (e.g., injection), intraperitoneal, intracisternal, intraarticular, intraperitoneal, intracerebral (intraparenchymal) and intraventricular), oral, nasal, vaginal, sublingual, intraocular, rectal, topical (e.g., transdermal), sublingual and inhalation, as well as direct injection into diseased tissue, such as tumor tissue.

[0087] In some aspects, administration includes topical administration to a target site in a subject. In some aspects, the target site comprises an inflammatory response or is susceptible to an inflammatory response. In some aspects, the target site has damage. The target site may be adjacent to a site with damage. The target site may include a site in the central nervous system. The target site may be the brain. The target site may have an arterial blockage. In some aspects, administration may be administered intra-arterially at the site of arterial blockage, for example, a catheter for clot retrieval may be used to administer the vesicles after clot retrieval.

[0088] In certain aspects, the vesicle composition can be injected into or near a tumor. In certain aspects, the composition of the anticancer agent and the composition of the vesicle can be administered to a subject simultaneously.

[0089] The present disclosure contemplates methods wherein a composition of the present disclosure is administered to a subject at least twice a day, at least once a day, at least once every 48 hours, at least once every 72 hours, at least once a week, at least once every 2 weeks, or once a month. Combination therapy

[0090] The present disclosure contemplates the use of the compositions provided herein in combination with one or more active therapeutic agents or other preventive or therapeutic modalities. In such combination therapies, the multiple active agents typically have different mechanisms of action. Such combination therapies may be particularly advantageous in that they allow the dosage of one or more agents to be reduced, thereby reducing or eliminating adverse effects associated with one or more agents; in addition, such combination therapies may have a synergistic therapeutic or preventive effect on potential diseases, disorders, or conditions.

[0091] As used herein, "combination" is meant to include therapies that can be administered separately, e.g., can be formulated separately for separate administration (e.g., as can be provided in a kit), as well as therapies that can be administered together in a single preparation (i.e., a "co-formulation").

[0092] In certain embodiments, the compositions of the present disclosure are sequentially administered or applied, for example, wherein one agent is administered before one or more other agents. In other embodiments, the compositions are administered simultaneously, for example, wherein two or more compositions are administered at the same time or about the same time; two or more compositions may be present in two or more separate preparations, or combined into a single preparation (i.e., a co-formulation). Regardless of whether two or more compositions are administered sequentially or simultaneously, for the purposes of the present disclosure, they are considered to be administered in combination.

[0093] The compositions of the present disclosure may be used in combination with other agents useful for treating, preventing, inhibiting, or ameliorating the diseases, disorders, or conditions noted herein, including those agents that are typically administered to subjects suffering from inflammation. Some Examples of Non-Limiting Aspects of the Disclosure

[0094] Some aspects (including embodiments) of the present subject matter described above may be beneficial alone or in combination with one or more other aspects or embodiments. Without limiting the foregoing description, certain non-limiting aspects of the present disclosure are provided below. As will be apparent to those skilled in the art after reading the present disclosure, each of the separately numbered aspects may be used or combined with any of the previous or following separately numbered aspects. This is intended to provide support for all such combinations of some aspects, and is not limited to the combinations of the aspects explicitly provided below: 1. A composition comprising: Vesicles prepared from a mammalian cell line genetically modified to overexpress a membrane protein selected from the group consisting of bifunctional heparan sulfate N-deacetylase / N-sulfotransferase 1, ferroptosis inhibitory protein 1, protein containing cysteine-rich and transmembrane domains, cadherin-6, solute carrier family 22 member 18, promethin, receptor-type tyrosine protein phosphatase κ, prolyl endopeptidase FAP, phospholipid transporting ATPase ID, ADP-ribosyl cyclase / cyclic ADP-ribose hydrolase 2, reticulin-2, ras-related protein Rap-1A, basigin, aldehyde dehydrogenase family 3 member B1, calcium homeoprotein-1, small VCP / p97 interacting protein, GTP-binding protein Rheb, lysophosphatidic acid receptor 1, pro-low-density lipoprotein receptor-related protein 1, receptor-type tyrosine protein phosphatase F, raftlin, guanine nucleotide binding protein G(q) subunit alpha, guanine guanine nucleotide binding protein subunit alpha-11, integrin alpha-8, circular decussate axon guidance receptor homolog 1, ADP-ribosylation factor 6, ephrin type B receptor 2, transforming protein RhoA, proto-oncogene tyrosine-protein kinase Src, synaptic vesicle protein homolog YKT6, Ras-related protein Rab-23, vascular cell adhesion protein 1, lymphocyte function-associated antigen 3, guanine nucleotide binding protein G(I) / G(S) / G(O) subunit gamma-12, 2',3'-cyclic nucleotide 3'-phosphodiesterase, receptor-type tyrosine-protein phosphatase eta, guanine nucleotide binding protein G(s) subunit alpha short isoform, ADP-ribosylation factor 5, mitochondrial calcium uniporter regulatory factor 1, nuclear mitotic apparatus protein 1, protein / nucleic acid deglycosylase DJ-1, V-type immunoglobulin domain-containing inhibitor of T-cell activation, CD276, MCAM, and phosphatidylserine synthase 2; and a pharmaceutically acceptable carrier, wherein the vesicles, when administered to a subject, reduce the level of at least one pro-inflammatory cytokine in the subject. 2. The composition of aspect 1, wherein the mammalian cell line is genetically modified to contain an exogenous nucleic acid sequence encoding the membrane protein. 3. The composition of aspect 2, wherein the exogenous nucleic acid sequence is operably linked to a heterologous promoter. 4. The composition of any one of aspects 1 to 3, wherein the mammalian cell line is genetically modified to overexpress at least two of the membrane proteins. 5. The composition of any one of aspects 1 to 3, wherein the mammalian cell line is genetically modified to overexpress three or more of the membrane proteins. 6. The composition of any one of aspects 1 to 5, wherein the composition comprises a first population of vesicles prepared by a first mammalian cell line genetically modified to overexpress a first membrane protein and a second population of vesicles prepared by a second mammalian cell line genetically modified to overexpress a second membrane protein, wherein the first membrane protein and the second membrane protein are independently selected from: bifunctional heparan sulfate N-deacetylase / N-sulfotransferase 1, ferroptosis inhibitory protein 1, protein containing cysteine-rich and transmembrane domains, cadherin-6, solute carrier family 22 member 18, promethin, receptor-type tyrosine protein phosphatase κ, prolyl endopeptidase FAP, phospholipid transporting ATPase ID, ADP-ribosyl cyclase / cyclic ADP-ribose hydrolase 2, reticulin-2, ras-related protein Rap-1A, basigin, aldehyde dehydrogenase family 3 member B1, calcium homeoprotein-1, small VCP / p97 interacting protein, GTP-binding protein Rheb, lysophosphatidic acid receptor 1, pre-low-density lipoprotein receptor-related protein 1, Receptor-type tyrosine protein phosphatase F, raftlin, guanine nucleotide binding protein G(q) subunit α, guanine nucleotide binding protein subunit α-11, integrin α-8, circular cross-linked axon guidance receptor homolog 1, ADP-ribosylation factor 6, ephrin B receptor type 2, transforming protein RhoA, proto-oncogene tyrosine protein kinase Src, synaptic vesicle protein homolog YKT6, Ras-related protein Rab-23, vascular cell adhesion protein 1, lymphocyte function-associated antigen 3, guanine nuclear Glycosyltransferase G(I) / G(S) / G(O) subunit gamma-12, 2',3'-cyclic nucleotide 3'-phosphodiesterase, receptor-type tyrosine-protein phosphatase eta, guanine nucleotide-binding protein G(s) subunit alpha short isoform, ADP-ribosylation factor 5, mitochondrial calcium uniporter regulatory factor 1, nuclear mitotic apparatus protein 1, protein / nucleic acid deglycosylase DJ-1, V-type immunoglobulin domain-containing inhibitor of T-cell activation, CD276, MCAM, and phosphatidylserine synthase 2. 7. The composition of aspect 6, further comprising a third population of vesicles produced by a third mammalian cell line genetically modified to overexpress a third membrane protein selected from the listed membrane proteins. 8. The composition of aspect 6, further comprising a plurality of vesicle populations prepared from a plurality of mammalian cell lines genetically modified to overexpress a membrane protein selected from the listed membrane proteins. 9. The composition of aspect 6, wherein the first mammalian cell line and / or the second mammalian cell line is further genetically modified to overexpress a different membrane protein selected from the listed membrane proteins. 10. The composition of any one of aspects 1 to 9, wherein the mammalian cell line is generated from a parent cell, wherein the parent cell is a mammalian cell line or a primary cell. 11. The composition of aspect 10, wherein the parental cell is a mammalian cell line, wherein the mammalian cell line is a HEK293 cell line, a CHO cell line, or an embryonic stem cell line. 12. The composition of aspect 10, wherein the parental cell is a primary cell, wherein the primary cell is a stem cell isolated from a subject. 13. The composition of aspect 12, wherein the stem cell is an embryonic stem cell, an induced pluripotent stem cell, a hematopoietic stem cell, a neuronal stem cell, a mesenchymal stem cell, a muscle stem cell or a skin stem cell. 14. The composition of any one of aspects 1 to 13, wherein the at least one proinflammatory cytokine comprises IL-2, IL-4, IL-6, IL-12, IL-12p70, IL-17, tumor necrosis factor alpha (TNF-α), or interferon gamma (IFN-γ). 15. The composition of any one of aspects 1 to 14, wherein the vesicles comprise extracellular vesicles (EVs), nanovesicles (NVs), synthetic eukaryotic vesicles (SyEVs), or a mixture of two or more of EVs, NVs and SyEVs. 16. A mammalian cell, wherein the mammalian cell is genetically modified to overexpress a membrane protein selected from the group consisting of bifunctional heparan sulfate N-deacetylase / N-sulfotransferase 1, ferroptosis inhibitory protein 1, a protein containing a cysteine-rich and transmembrane domain, cadherin-6, solute carrier family 22 member 18, promethin, receptor-type tyrosine protein phosphatase κ, prolyl endopeptidase FAP, phospholipid transporting ATPase ID, ADP-ribosyl cyclase / cyclic ADP-ribose hydrolase 2, reticulin-2, ras-related protein Rap-1A, basigin, aldehyde dehydrogenase family 3 member B1, calcium homeoprotein-1, small VCP / p97 interacting protein, GTP-binding protein Rheb, lysophosphatidic acid receptor 1, pre-low-density lipoprotein receptor-related protein 1, receptor-type tyrosine protein phosphatase F, raftlin, guanine nucleotide binding protein G(q) subunit alpha, Guanine nucleotide binding protein subunit alpha-11, integrin alpha-8, circular cross-linked axon guidance receptor homolog 1, ADP-ribosylation factor 6, ephrin type B receptor 2, transforming protein RhoA, proto-oncogene tyrosine protein kinase Src, synaptic vesicle protein homolog YKT6, Ras-related protein Rab-23, vascular cell adhesion protein 1, lymphocyte function-associated antigen 3, guanine nucleotide binding protein G(I) / G(S) / G(O) subunit gamma-12, 2',3'-cyclic nucleotide 3'-phosphodiesterase, receptor-type tyrosine-protein phosphatase eta, guanine nucleotide-binding protein G(s) subunit alpha short isoform, ADP-ribosylation factor 5, mitochondrial calcium uniporter regulatory factor 1, nuclear mitotic apparatus protein 1, protein / nucleic acid deglycosylase DJ-1, V-type immunoglobulin domain-containing inhibitor of T-cell activation, CD276, MCAM, and phosphatidylserine synthase 2. 17. The mammalian cell line of aspect 16, wherein the mammalian cell line is genetically modified to contain an exogenous nucleic acid sequence encoding the membrane protein. 18. The mammalian cell line of aspect 17, wherein the exogenous nucleic acid sequence is operably linked to a heterologous promoter. 19. The mammalian cell line of any one of aspects 16 to 18, wherein the mammalian cell line is genetically modified to overexpress at least two of the membrane proteins. 20. The mammalian cell line of any one of aspects 16 to 18, wherein the mammalian cell line is genetically modified to overexpress three or more of the membrane proteins. 21. The mammalian cell line of any one of aspects 16 to 18, wherein the mammalian cell line is generated from a parent cell, wherein the parent cell is a mammalian cell line or a primary cell. 22. The mammalian cell line of aspect 21, wherein the parent cell is a mammalian cell line, wherein the mammalian cell line is a HEK293 cell line, a CHO cell line, or an embryonic stem cell line. 23. The mammalian cell line of aspect 21, wherein the parental cell is a primary cell, wherein the primary cell is a stem cell isolated from a subject. 24. The mammalian cell line of aspect 23, wherein the stem cell is an embryonic stem cell, an induced pluripotent stem cell, a hematopoietic stem cell, a neuronal stem cell, a mesenchymal stem cell, a muscle stem cell, or a skin stem cell. 25. A method for reducing inflammation in a subject in need thereof, the method comprising: administering to the subject an effective amount of the composition of any one of aspects 1 to 15, wherein the administering reduces at least one proinflammatory cytokine in the subject. 26. The method of aspect 25, wherein the subject suffers from or is susceptible to an inflammatory-related disorder selected from the group consisting of cancer, multiple sclerosis, psoriasis, dry eye, asthma, sepsis, infection, rheumatoid arthritis, ulcerative colitis, Crohn's disease, tuberculosis, hepatitis, sinusitis, autoimmune disease, inflammatory bowel disease, pelvic inflammatory disease, ulcer, atherosclerosis, erythema, necrosis, vasculitis, ankylosing spondylitis, connective tissue disease, kidney disease, sarcoidosis, thyroiditis, bone marrow disease, osteoporosis ... Arthritis, rheumatic diseases, chronic inflammatory disorders, demyelinating polyneuropathy, pancreatitis, psoriatic arthritis, periodontitis, Behcet's disease, sinusitis, polymyalgia rheumatica, nephritis, diverticulitis, granulomatosis with polyangiitis, granulomas, encephalitis, immune-mediated inflammatory diseases, esophagitis, gout, uveitis, myopathy, gallbladder disease, periodic fever syndromes, interstitial cystitis, peritonitis, appendicitis, Parkinson's disease, Alzheimer's disease, systemic lupus erythematosus, fibromyalgia, diverticulitis, dermatitis, and ankylosing spondylitis. 27. The method of aspect 26, wherein the inflammatory-related disorder is asthma. 28. The method of aspect 26, wherein the inflammation-related disorder is sepsis. 29. The method of aspect 26, wherein the inflammatory-related disorder is an infection. 30. The method of aspect 29, wherein the infection is a bacterial, viral or parasitic infection. 32. The method of any one of aspects 25 to 30, wherein the method further comprises administering a therapeutic agent to the subject. 33. The method of aspect 32, wherein the method comprises administering the composition and the therapeutic agent to the subject. 34. The method of aspect 32, wherein the method comprises administering the composition to the subject, wherein the vesicles comprise the therapeutic agent. 35. The method of any one of aspects 32 to 34, wherein the therapeutic agent comprises a small molecule, a peptide, a nucleic acid, or a polypeptide. 36. The method of any one of aspects 32 to 34, wherein the administration comprises intravenous, subcutaneous, intramuscular, intraperitoneal, intraarterial, intraarticular, intracerebral (intraparenchymal), or intracerebroventricular administration. 37. The method of any one of aspects 32 to 34, wherein the administering comprises local administration to a target site in the subject. Example

[0095] The following examples are presented so as to provide one of ordinary skill in the art with a complete disclosure and description of how to make and use the invention, and are not intended to limit the scope of what the inventors believe to be their invention, nor are they intended to represent that the experiments below are all or the only experiments performed. Efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, temperatures, etc.), but some experimental errors and deviations should be taken into account. Unless otherwise indicated, parts are parts by weight, molecular weight is weight average molecular weight, temperature is degrees Celsius, and pressure is at or near atmospheric pressure. Standard abbreviations may be used, such as bp, base pair; kb, kilobase; pl, picoliter; s or sec, second; min, minute; h or hr, hour; aa, amino acid; kb, kilobase; bp, base pair; nt, nucleotide; im, intramuscular; ip, intraperitoneal; sc, subcutaneous; and the like. Example 1: Anti-inflammatory activity of EV, NV and SyEV in bacterial outer membrane vesicle-induced inflammation Methods Preparation of EV, NV, and SyEV

[0096] Preparation of EVs :The MSC cell-derived supernatant was centrifuged at 300×g for 10 minutes and at 2,000×g for 20 minutes at 4°C to remove cell debris. The resulting supernatant was ultracentrifuged at 16,500×g for 20 minutes and at 120,000×g for 2.5 hours at 4°C to collect large vesicles and small vesicles. Only small vesicles were applied to 4mL 50% iodixanol, followed by adding 4mL 30% iodixanol and 2mL 10% iodixanol to the ultracentrifuge tube. The layer formed between 10% and 30% iodixanol after ultracentrifugation at 100,000×g for 2 hours was collected. Finally, the vesicles were considered to be EVs ( Figure 1 ).

[0097] Preparation of NV and SyEV MSCs were cultured at 5×10 6The density of individual cells / mL is resuspended in the phosphate buffered saline of 10mL in total. Make cell suspension pass through each membrane filter (in this order) of 10 μm, 5 μm and 1 μm with pore size 5 times. Respectively by 1mL and 2mL 50% and 10% iodixanol solution (Axis-Shield PoC AS), then the cell suspension effluent from membrane filter of 7mL is added to each 10mL ultracentrifuge tube in sequence. The layer formed between 50% iodixanol and 10% iodixanol after 2 hours of ultracentrifugation at 100,000 × g is collected and regarded as NV. NV is hatched 1 hour under 25 degrees with high pH solution (200mMNa2CO3, pH 14.0). This solution is applied to 4mL 50% iodixanol, then 4mL 30% iodixanol and 2mL 10% iodixanol are added to ultracentrifuge tube. The layer formed between 10% and 30% iodixanol after ultracentrifugation at 100,000×g for 2 h was collected. Finally, the sample was sonicated for 30 min and considered as SyEV ( Figure 1 ).

[0098] Quantification of vesicles : The protein concentration of the vesicles was determined using the Bradford dye assay (Bio-Rad Laboratories). The particle concentration was assessed by a ZetaView analyzer (Particle Metrix GmbH). The measurements were evaluated in triplicate and each individual data was obtained from two stable layers, each layer measured five times. In all measurements, the camera sensitivity was configured to 70. The data were analyzed using ZetaView analysis software version 8.2.30.1.

[0099] RAW 264.7 cytokines: Mouse macrophage cell line RAW 264.7 (1×10 5 ) were inoculated into 24-well plates and then treated with E. coli outer membrane vesicles (OMV; 100 ng / mL) for 3 h to induce inflammation. 7 , 10 8 , 10 9 ) were applied to the cells, and the supernatant concentrations of TNF-α and IL-6 were measured by ELISA kits (R&D systems) 15 h later. result

[0100] Bacterial OMVs have been implicated as infectious agents that induce inflammation. SyEVs significantly reduced OMV-induced release of TNF-α and IL-6 from RAW 264.7 cells compared with EVs or NVs, suggesting that all of these vesicles share common proteins associated with therapeutic efficacy (Figure 2). Example 2: Comparative proteomic analysis of MSC-derived EV, NV and SyEV proteins

[0101] LC-MS / MS analysis Two biological replicates (30 μg) of EV, NV, and SyEV were digested with trypsin using the filter-aided sample preparation (FASP) method and C18 spin column desalting according to the manufacturer's instructions. All fractions were dried on a Speedvac, reconstituted in 3% acetonitrile and 0.2% formic acid, and analyzed on an Orbitrap Fusion Tribrid mass spectrometer interfaced with an Easy-nLC 1200 (Thermo Fisher Scientific). Peptides were trapped on an Acclaim Pepmap 100 C18 trap column (100 μm × 2 cm, particle size 5 μm; ThermoFischer Scientific) and separated on an in-house packed C18 analytical column (75 μm × 30 cm, particle size 3 μm) using a gradient from 5% to 32% B in 75 minutes, from 32% to 100% B in 5 minutes, solvent A was 0.2% formic acid and solvent B was 80% acetonitrile and 0.2% formic acid. Precursor ion mass spectra were recorded at a resolution of 120,000, the most intense precursor ion was selected, fragmented using collision induced dissociation (CID) at a collision energy setting of 35, and spectra and MS / MS spectra were recorded in the ion trap at a maximum injection time of 40 ms and an isolation window of 0.7 Da. Charge states 2 to 7 were selected for fragmentation, dynamic exclusion was set to 45 seconds, and tolerance was 10 ppm. MS3 spectra for reporter ion quantification were recorded at a resolution of 50,000 under HCD fragmentation at a collision energy of 60 using simultaneous precursor selection of the 7 most abundant MS / MS fragments with a maximum injection time of 100 ms.

[0102] Database search: Data analysis was performed using Proteome Discoverer version 2.2 (Thermo Fisher Scientific, Waltham, MA). Database searches were performed against the Swissprot Homo sapiens database. Mascot 2.5.1 (Matrix Science) was used as a search engine with a precursor mass tolerance of 10 ppm and a fragment mass tolerance of 0.6 Da; one missed cleavage was accepted, single oxidation on methionine was set as a variable modification, and methylsulfonation on cysteine ​​was set as a fixed modification. Percolator was used to validate the identification results, with a strict target false discovery rate of 1%, and proteins were considered only when identified in all replicates. result

[0103] A total of 4686 proteins were identified in the mass spectrometry analysis. Of these 4686 proteins, 3661 proteins were quantified in all six samples. Next, the gene ontology (cellular components) of all proteins were downloaded from Uniprot and the GO term “integral component of the membrane” was selected as it is defined as “a component of the membrane composed of gene products and protein complexes, at least a portion of whose peptide sequences are buried in the hydrophobic region of the membrane”. This means that the proteins are true membrane proteins. Of our 3661 proteins, 605 proteins were associated with this GO term. Next, we determined the fold changes of these 605 membrane proteins between the three vesicle types. We set the cutoff value to a fold change of 1.5. This means that proteins with a fold change higher than +1.5 between the two vesicle types were considered up- or down-regulated, while proteins with a fold change less than 1.5 were considered unchanged ( Figure 3 Next, we compared proteins that were considered unchanged in the three comparisons (189 proteins in SyEV vs NV, 133 proteins in SyEV vs EV, and 317 proteins in NV vs EV) ( Figure 4). Then it was shown that 41 proteins were considered to be unchanged in all three comparisons and could therefore be considered to have similar expression in all vesicle types (Figure 5). Interestingly, bifunctional heparan sulfate N-deacetylase / N-sulfotransferase 1 and ferroptosis inhibitory protein 1 are known to be associated with immunosuppression and regulation of repair processes (Cell Metab. 2014 Nov 4; 20(5): 813-826; Nature. 2019 Nov; 575(7784): 693-698). In addition, 4, 14, and 9 proteins were unchanged in two of the three comparisons. These may also (along with 10 proteins) be proteins responsible for the anti-inflammatory effects observed in Figure 2. In particular, V-type immunoglobulin domain-containing inhibitors of T cell activation, CD276, MCAM, and phosphatidylserine synthase 2 have been shown to be involved in immune regulation and anti-oxidative stress processes (Front Immunol. 2020 Oct 15; 11: 580187; Nat Immunol. 2003 Sep; 4(9): 899-906; Stem Cells. 2020 Aug; 38(8): 1034-1049; Cell Death Differ. 2016 Jun; 23(6): 962-78).

Claims

1. A composition comprising: Vesicles prepared from a mammalian cell line genetically modified to overexpress a membrane protein selected from the group consisting of bifunctional heparan sulfate N-deacetylase / N-sulfotransferase 1 (NDST1), ferroptosis inhibitory protein 1 (AIFM2), cysteine-rich and transmembrane domain-containing protein 1 (CYSTM1), cadherin-6 (CDH6), solute carrier family 22 member 18 (SLC22A18), promethin (TMEM159), receptor-type tyrosine protein phosphatase kappa (PTPRK), prolyl endopeptidase FAP (FAP), phospholipid transporting ATPase ID (ATP8B2), ADP-ribosyl cyclase / cyclic AD P-ribose hydrolase 2 (BST1), reticulin-2 (RTN2), ras-related protein Rap-1A (RAP1A), basigin (BSG), aldehyde dehydrogenase family 3 member B1 (ALDH3B1), calcium homeostasis protein-1 (CLSTN1), small VCP / p97 interacting protein (SVIP), GTP-binding protein Rheb (RHEB), lysophosphatidic acid receptor 1 (LPAR1), pro-low-density lipoprotein receptor-related protein 1 (LRP1), receptor-type tyrosine-protein phosphatase F (PTPRF), raftlin (RFTN1), guanine nucleotide binding protein G (q) subunit alpha (GNAQ), guanine nucleotide binding protein G (q) subunit alpha (GNAQ), Purine nucleotide binding protein subunit alpha-11 (GNA11), integrin alpha-8 (ITGA8), circular cross-linked axon guidance receptor homolog 1 (ROBO1), ADP-ribosylation factor 6 (ARF6), ephrin type B receptor 2 (EPHB2), transforming protein RhoA (RHOA), proto-oncogene tyrosine protein kinase Src (SRC), synaptic vesicle protein homolog YKT6 (YKT6), Ras-related protein Rab-23 (RAB23), vascular cell adhesion protein 1 (VCAM1), lymphocyte function-associated antigen 3 (CD58), guanine nucleotide binding protein G (I) / G (S) / G (O) subunit gamma-12 (GNG12), 2',3'-cyclic nucleotide 3'-phosphodiesterase (CNP), receptor-type tyrosine-protein phosphatase eta (PTPRJ), guanine nucleotide-binding protein G(s) subunit alpha short isoform (GNAS), ADP-ribosylation factor 5 (ARF5), mitochondrial calcium uniporter regulatory factor 1 (MCUR1), nuclear mitotic apparatus protein 1 (NUMA1), protein / nucleic acid deglycosylase DJ-1 (PARK7), V-type immunoglobulin domain-containing inhibitor of T-cell activation (VISTA), CD276, cell surface glycoprotein MUC18 (MCAM), and phosphatidylserine synthase 2 (PTDSS2); and a pharmaceutically acceptable carrier, wherein the vesicles, when administered to a subject, reduce the level of at least one pro-inflammatory cytokine in the subject.

2. The composition of claim 1, wherein the mammalian cell line is genetically modified to contain an exogenous nucleic acid sequence encoding the membrane protein.

3. The composition of claim 2, wherein the exogenous nucleic acid sequence is operably linked to a heterologous promoter.

4. The composition of any one of claims 1 to 3, wherein the mammalian cell line is genetically modified to overexpress at least two of the membrane proteins.

5. The composition of any one of claims 1 to 3, wherein the mammalian cell line is genetically modified to overexpress three or more of the membrane proteins.

6. The composition of any one of claims 1 to 5, wherein the composition comprises a first population of vesicles prepared by a first mammalian cell line genetically modified to overexpress a first membrane protein and a second population of vesicles prepared by a second mammalian cell line genetically modified to overexpress a second membrane protein, wherein the first membrane protein and the second membrane protein are independently selected from: bifunctional heparan sulfate N-deacetylase / N-sulfotransferase 1, ferroptosis inhibitory protein 1, protein containing cysteine-rich and transmembrane domains, cadherin-6, solute carrier family 22 member 18, promethin, receptor-type tyrosine-protein phosphatase κ, prolyl endopeptidase FAP, phospholipid transporting ATPase ID, ADP-ribosyl cyclase / cyclic ADP-ribose hydrolase 2, reticulin-2, ras-related protein Rap-1A, basigin, aldehyde dehydrogenase family 3 member B1, calcium homeoprotein-1, small VCP / p97 interacting protein, GTP-binding protein Rheb, lysophosphatidic acid receptor 1, pre-low-density lipoprotein receptor-related protein 1 , receptor-type tyrosine protein phosphatase F, raftlin, guanine nucleotide binding protein G(q) subunit α, guanine nucleotide binding protein subunit α-11, integrin α-8, circular cross-linked axon guidance receptor homolog 1, ADP-ribosylation factor 6, ephrin B receptor type 2, transforming protein RhoA, proto-oncogene tyrosine protein kinase Src, synaptic vesicle protein homolog YKT6, Ras-related protein Rab-23, vascular cell adhesion protein 1, lymphocyte function-associated antigen 3, guanine nuclear Glycosyltransferase G(I) / G(S) / G(O) subunit gamma-12, 2',3'-cyclic nucleotide 3'-phosphodiesterase, receptor-type tyrosine-protein phosphatase eta, guanine nucleotide-binding protein G(s) subunit alpha short isoform, ADP-ribosylation factor 5, mitochondrial calcium uniporter regulatory factor 1, nuclear mitotic apparatus protein 1, protein / nucleic acid deglycosylase DJ-1, V-type immunoglobulin domain-containing inhibitor of T-cell activation, CD276, MCAM, and phosphatidylserine synthase 2.

7. The composition of claim 6, further comprising a third population of vesicles produced from a third mammalian cell line genetically modified to overexpress a third membrane protein selected from the listed membrane proteins.

8. The composition of claim 6, further comprising a plurality of vesicle populations produced from a plurality of mammalian cell lines genetically modified to overexpress a membrane protein selected from the listed membrane proteins.

9. The composition of claim 6, wherein the first mammalian cell line and / or the second mammalian cell line is further genetically modified to overexpress a different membrane protein selected from the listed membrane proteins.

10. The composition of any one of claims 1 to 9, wherein the mammalian cell line is generated from a parent cell, wherein the parent cell is a mammalian cell line or a primary cell.

11. The composition of claim 10, wherein the parental cell is a mammalian cell line, wherein the mammalian cell line is a HEK293 cell line, a CHO cell line, or an embryonic stem cell line.

12. The composition of claim 10, wherein the parental cell is a primary cell, wherein the primary cell is a stem cell isolated from a subject.

13. The composition of claim 12, wherein the stem cell is an embryonic stem cell, an induced pluripotent stem cell, a hematopoietic stem cell, a neuronal stem cell, a mesenchymal stem cell, a muscle stem cell, or a skin stem cell.

14. The composition of any one of claims 1 to 13, wherein the at least one proinflammatory cytokine comprises IL-2, IL-4, IL-6, IL-12, IL-12p70, IL-17, tumor necrosis factor alpha (TNF-α), or interferon gamma (IFN-γ).

15. The composition of any one of claims 1 to 14, wherein the vesicles comprise extracellular vesicles (EVs), nanovesicles (NVs), synthetic eukaryotic vesicles (SyEVs), or a mixture of two or more of EVs, NVs, and SyEVs.

16. A mammalian cell, wherein the mammalian cell is genetically modified to overexpress a membrane protein selected from the group consisting of bifunctional heparan sulfate N-deacetylase / N-sulfotransferase 1, ferroptosis inhibitory protein 1, a protein containing a cysteine-rich and transmembrane domain, cadherin-6, solute carrier family 22 member 18, promethin, receptor-type tyrosine protein phosphatase κ, prolyl endopeptidase FAP, phospholipid transporting ATPase ID, ADP-ribosyl cyclase / cyclic ADP-ribose hydrolase 2, reticulin-2, ras-related protein Rap-1A, basigin, aldehyde dehydrogenase family 3 member B1, calcium homeoprotein-1, small VCP / p97 interacting protein, GTP-binding protein Rheb, lysophosphatidic acid receptor 1, pre-low-density lipoprotein receptor-related protein 1, receptor-type tyrosine protein phosphatase F, raftlin, guanine nucleotide binding protein G(q) subunit alpha, Guanine nucleotide binding protein subunit alpha-11, integrin alpha-8, circular cross-linked axon guidance receptor homolog 1, ADP-ribosylation factor 6, ephrin type B receptor 2, transforming protein RhoA, proto-oncogene tyrosine protein kinase Src, synaptic vesicle protein homolog YKT6, Ras-related protein Rab-23, vascular cell adhesion protein 1, lymphocyte function-associated antigen 3, guanine nucleotide binding protein G(I) / G(S) / G(O) subunit gamma-12, 2',3'-cyclic nucleotide 3'-phosphodiesterase, receptor-type tyrosine-protein phosphatase eta, guanine nucleotide-binding protein G(s) subunit alpha short isoform, ADP-ribosylation factor 5, mitochondrial calcium uniporter regulatory factor 1, nuclear mitotic apparatus protein 1, protein / nucleic acid deglycosylase DJ-1, V-type immunoglobulin domain-containing inhibitor of T-cell activation, CD276, MCAM, and phosphatidylserine synthase 2.

17. The mammalian cell line of claim 16, wherein the mammalian cell line is genetically modified to contain an exogenous nucleic acid sequence encoding the membrane protein.

18. The mammalian cell line of claim 17, wherein the exogenous nucleic acid sequence is operably linked to a heterologous promoter.

19. The mammalian cell line of any one of claims 16 to 18, wherein the mammalian cell line is genetically modified to overexpress at least two of the membrane proteins.

20. The mammalian cell line of any one of claims 16 to 18, wherein the mammalian cell line is genetically modified to overexpress three or more of the membrane proteins.

21. The mammalian cell line of any one of claims 16 to 18, wherein the mammalian cell line is generated from a parent cell, wherein the parent cell is a mammalian cell line or a primary cell.

22. The mammalian cell line of claim 21, wherein the parent cell is a mammalian cell line, wherein the mammalian cell line is a HEK293 cell line, a CHO cell line, or an embryonic stem cell line.

23. The mammalian cell line of claim 21, wherein the parental cell is a primary cell, wherein the primary cell is a stem cell isolated from a subject.

24. The mammalian cell line of claim 23, wherein the stem cell is an embryonic stem cell, an induced pluripotent stem cell, a hematopoietic stem cell, a neuronal stem cell, a mesenchymal stem cell, a muscle stem cell, or a skin stem cell.

25. A method for reducing inflammation in a subject in need thereof, the method comprising: administering to the subject an effective amount of the composition of any one of claims 1 to 15, wherein the administering reduces at least one proinflammatory cytokine in the subject.

26. The method of claim 25, wherein the subject suffers from or is susceptible to an inflammatory-related disorder selected from the group consisting of cancer, multiple sclerosis, psoriasis, dry eye, asthma, sepsis, infection, rheumatoid arthritis, ulcerative colitis, Crohn's disease, tuberculosis, hepatitis, sinusitis, autoimmune disease, inflammatory bowel disease, pelvic inflammatory disease, ulcers, atherosclerosis, erythema, necrosis, vasculitis, ankylosing spondylitis, connective tissue disease, kidney disease, sarcoidosis, thyroiditis, Osteoarthritis, rheumatic diseases, chronic inflammatory conditions, demyelinating polyneuropathy, pancreatitis, psoriatic arthritis, periodontitis, Behcet's disease, sinusitis, polymyalgia rheumatica, nephritis, diverticulitis, granulomatosis with polyangiitis, granulomas, encephalitis, immune-mediated inflammatory diseases, esophagitis, gout, uveitis, myopathy, gallbladder disease, periodic fever syndromes, interstitial cystitis, peritonitis, appendicitis, Parkinson's disease, Alzheimer's disease, systemic lupus erythematosus, fibromyalgia, diverticulitis, dermatitis, and ankylosing spondylitis.

27. The method of claim 26, wherein the inflammatory-related disorder is an inflammatory respiratory disease.

28. The method of claim 26, wherein the inflammatory-related disorder is sepsis / cytokine storm.

29. The method of claim 26, wherein the inflammatory-related disorder is an infection.

30. The method of claim 29, wherein the infection is a bacterial, viral, or parasitic infection.

31. The method of any one of claims 25 to 30, wherein the method further comprises administering a therapeutic agent to the subject.

32. The method of claim 32, wherein the method comprises administering the composition and the therapeutic agent to the subject.

33. The method of claim 32, wherein the method comprises administering the composition to the subject, wherein the vesicles comprise the therapeutic agent.

34. The method of any one of claims 32 to 34, wherein the therapeutic agent comprises a small molecule, a peptide, a nucleic acid, or a polypeptide.

35. The method of any one of claims 32 to 34, wherein the administration comprises intravenous, subcutaneous, intramuscular, intraperitoneal, intraarterial, intraarticular, intracerebral (intraparenchymal), or intracerebroventricular administration.

36. The method of any one of claims 32 to 34, wherein the administering comprises local administration to a target site in the subject.